Medicine and Health

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

C. F. Friedman, B. L. Manning-geist, et al.

A phase 2 study revealed that nivolumab induced an impressive objective response rate of 58.8% and a 64.7% progression-free survival in patients with dMMR uterine or ovarian cancers. This research by Claire F. Friedman and colleagues underscores the promising genetic factors and tumor microenvironment influences that might enhance the efficacy of PD-1 blockade in treating these cancers.... show more

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

M. Schuler, K. Cuppens, et al.

Medicine and Health

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

R. J. Kelly, B. V. Landon, et al.

Medicine and Health

Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial

A. Podadera-herreros, A. P. A. Larriva, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny